Polar Asset Management Partners’s Aspire Biopharma ASBP Stock Holding History

Polar Asset Management Partners’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-146	Closed	-$1.84M	–	1083
2023 Q1	$1.84M	Hold	146	–	–	0.03%	519
2022 Q4	$1.81M	Hold	146	–	–	0.02%	639
2022 Q3	$1.78M	Buy	+146	New	+$1.76M	0.02%	709

Other funds holding ASBP

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Hudson Bay Capital Management

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Polar Asset Management Partners's ASBP Position: Q2 2023 in Review

Polar Asset Management Partners sold out of Aspire Biopharma (ASBP) in Q2 2023, closing a stake of 146 shares — an estimated $1.84M sold.

Polar Asset Management Partners first reported a position in ASBP in Q3 2022 and held it in 3 quarters. The position peaked at $1.84M in Q1 2023. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2023.

Polar Asset Management Partners reported no remaining Aspire Biopharma position as of Q2 2023 after selling out during the quarter.
Polar Asset Management Partners sold 146 Aspire Biopharma shares in Q2 2023, an estimated $1.84M.
Polar Asset Management Partners first reported a position in Aspire Biopharma in Q3 2022 and held it in 3 quarters.
Polar Asset Management Partners's Aspire Biopharma position peaked at $1.84M in Q1 2023.
14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2023.

Based on Polar Asset Management Partners's 13F filing for Q2 2023, filed 14 Aug 2023.